Revvity, Inc. (NYSE: RVTY) — A Reborn Life-Sciences Compounder Priced for Its Growth to Never Re-Accelerate

Report date: 2026-07-18 · Independent equity research Company: Revvity, Inc. (formerly PerkinElmer, Inc.) · Exchange/Ticker: NYSE: RVTY · Sector: Health Care — Life Sciences Tools & Diagnostics Price at analysis: ~$110 · Market cap: ~$12.3B · Enterprise value: ~$14.6B · FY (Dec) 2025 revenue: $2,856M

⚡ Claude’s Take

This block is the author’s own subjective opinion, offered as independent analysis and general information. It is not investment advice. The analytical body that follows takes no position and carries no price target, by design.

Verdict: HOLD / accumulate-on-weakness. A genuinely good business at a fair-not-cheap price — I would be a buyer into the low-$90s / high-$80s (≈17–18× forward adjusted EPS of ~$5.25), a holder at ~$110, and I would not chase it toward $130. Conviction: medium.

Revvity is the rare “quality-at-a-discount” name that is actually mispriced by the accounting, not by the business. Screened on GAAP, it looks dreadful — a 45–52× P/E, a ~4% ROE, a ~3% ROIC and a negative tangible book. All of that is the amortization shadow of two large deals (EUROIMMUN, BioLegend) grinding through the P&L. Look at cash: ~28% adjusted operating margins, ~$600M of free cash flow on $2.9B of sales (a ~5% FCF yield), a razor/razorblade newborn-screening franchise with genuine regulatory entrenchment, and ~87% cash conversion heading higher. Management is shrinking the share count aggressively (126M→112M since 2021), pruning the portfolio hard (sold the legacy Analytical/Applied business to New Mountain in 2023; now exiting a structurally-broken China immunodiagnostics business at ~6% of revenue), and financing it all on 2.6%-fixed debt that is a hidden asset in a 4%+ world. The framing is abandoned-value-recovering, not falling-knife — the stock is ~45% below its 2021 COVID-diagnostics peak, was a multi-year underperformer (−6%/yr over five years), but has bottomed and put up its strongest quarter in years (+3% organic, a beat, and a positive pharma/biotech turn).

What keeps me at HOLD rather than BUY is that the market is not obviously wrong. Revvity’s organic growth is low-single-digit (3–4% guided), structurally below Danaher/Thermo/Mettler, and its two halves are uneven: a world-class newborn-screening/immunodiagnostics moat sits next to a reagents-and-instruments Life Sciences business that is more commoditized and cyclically hostage to pharma/biotech and academic budgets. At ~21× forward earnings you are paying a deserved discount to the group, not a gift. The bull needs organic growth to re-accelerate toward mid-single-digits and margins to march to ~30%+; the bear needs the tools cycle to stay soft and the BioLegend deal’s returns to keep looking mediocre on a cash-ROIC basis. Bullish trigger: two-plus quarters of accelerating organic growth (4%+ with instrument demand inflecting). Bearish trigger: organic growth stalls back toward ~1–2% and buybacks are funded by re-levering rather than FCF. Tag: “The accounting hides the cash — but not the growth problem.”

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are Facts; attributed causes are Interpretation.

Over the trailing five years RVTY has been a near-textbook COVID-boom-to-bust round trip that never fully recovered. From ~$152 in mid-2021 the stock spiked to an all-time high of $198.75 (Dec 2021) on peak COVID-diagnostics earnings and the just-closed BioLegend deal, then bled for two years — through a rate-driven de-rating of expensive tools names and the post-COVID/biotech-capex hangover — to a low of $81.47 (Oct 2023). It has since chopped in a wide ~$82–128 band with no durable trend, and today sits at ~$110, still ~45% below its high and in the early innings of a recovery off an April 2026 low. 52-week range ~$82–118; the stock is above both its 200-EMA (~$99) and 50-EMA (~$104). Beta ~1.08; long-run alpha negative (~−0.23).

1. 2021 melt-up — COVID-testing earnings and the BioLegend acquisition carried the stock to its still-unbeaten $198.75 peak amid a euphoric growth-tools tape.
2. 2022 de-rating — as the Fed hiked, the market repriced high-multiple tools names while COVID revenue rolled off — a multiple and earnings hit.
3. 2022–23 portfolio remake — the ~$2.45B New Mountain divestiture (Mar 2023) and the rebrand (Apr 2023) reshaped the company into a life-sciences/diagnostics pure-play but did not arrest the drift.
4. Oct 2023 capitulation — the Q3’23 miss and FY-guidance cut drove a ~14–16% single-day drop to $81.47, the lowest since April 2020, on biotech-capex and China weakness.
5. 2023–24 rebound — a December 2023 rate-pivot rally (+23% that month) plus a Q2’24 beat lifted shares back toward $125.
6. 2025 tariff/funding scare — renewed pharma-capex/biotech-funding fears, tariff risk and the China overhang re-derated the whole tools group.
7. 2025–26 basing — persistent China policy headwinds and a second tariff scare pushed the stock to a fresh 52-week low ($82.21), nearly matching the 2023 bottom.
8. 2026 recovery — the May 5 Q1’26 beat (+3% organic, ~+6% ex-China) and the decision to divest the China immunodx drag sparked a ~+21% May and carried shares back to ~$110.

1. Executive Summary

Revvity, Inc. is the successor to PerkinElmer: in early 2023 the company sold its legacy Analytical, Applied and Enterprise Services businesses to New Mountain Capital for ~$2.45B, renamed itself Revvity, and refocused as a ~$2.9B-revenue, two-segment life-sciences-tools-and-diagnostics company. The two halves are roughly equal: Life Sciences Solutions & Software (~$1.43B, ~50% — instruments, reagents including the BioLegend antibody/flow-cytometry catalog, and the Signals informatics/SaaS platform) and Diagnostics (~$1.42B, ~50% — EUROIMMUN autoimmune and infectious-disease immunodiagnostics, DELFIA/GSP newborn-and-prenatal screening, and applied genomics).

The central analytical fact about Revvity is the gap between its GAAP and its cash economics. GAAP FY2025 diluted EPS was $2.07, a ~4% ROE and a ~3% ROIC; on that basis the stock trades at ~50× earnings and looks like a value-destroyer. But the GAAP figures are dominated by non-cash amortization of acquired intangibles (a ~$8.96B goodwill-and-intangible stack from the EUROIMMUN and BioLegend acquisitions) and by discrete items. On a cash basis the business runs ~28% adjusted operating margins, generates ~$600M of free cash flow (~20% margin, ~87% conversion of adjusted net income), and guides to FY2026 adjusted EPS of $5.20–5.30. At ~$110 that is ~21× forward adjusted earnings, ~16× adjusted EBITDA and a ~5% free-cash-flow yield — a clear discount to Danaher, Thermo Fisher and Mettler-Toledo.

The bull case is a quality compounder bought while the accounting and the cycle obscure it: a defensible newborn-screening/immunodiagnostics franchise, improving margins, disciplined portfolio pruning (New Mountain in 2023; the ~6%-of-revenue China immunodiagnostics exit announced in 2026), and an aggressive, FCF-funded buyback shrinking the share count ~11% since 2021. The bear case is that the discount is earned: organic growth is structurally low-single-digit and below peers, roughly half the business (Life Sciences reagents/instruments) is cyclically exposed and less differentiated, the balance sheet still carries ~3× net leverage against a thin GAAP earnings base, and the marquee BioLegend deal has yet to prove accretive on a cash-return basis. This report takes no position; it lays out the evidence for both.

2. Business Overview

What Revvity does. Revvity develops, manufactures and sells instruments, reagents, assays, software and services across two end-markets: life-sciences research and clinical diagnostics. It is the “new” company carved out of PerkinElmer’s higher-growth, higher-margin core after the 2023 divestiture of the legacy analytical-instruments and applied-markets businesses (chromatography, mass spec, environmental/industrial testing, and enterprise/OneSource lab services) to New Mountain Capital. The retained business is deliberately concentrated in franchises with recurring-revenue characteristics and, in diagnostics, regulatory entrenchment.

Segment 1 — Life Sciences Solutions & Software (~$1,431M FY2025, ~50% of revenue, +2% YoY). This segment sells:

• Reagents and consumables — most importantly the BioLegend catalog (antibodies, recombinant proteins, flow-cytometry and multiomics reagents) acquired in 2021, plus legacy PerkinElmer detection/labeling reagents (AlphaLISA, DELFIA research reagents) and Dharmacon RNAi tools. Reagents are the recurring, high-margin, high-quality-of-revenue core.
• Instruments and automation — plate readers, imaging (IVIS, Operetta/Opera high-content), automated liquid handling (JANUS, Zephyr), cell counting (Cellometer, Cellaca) and nucleic-acid extraction (chemagic). Instruments are lumpier, capex-sensitive and lower-margin, but pull through consumables.
• Signals software — a cloud/SaaS informatics platform (Signals Notebook, Signals VitroVivo, and newer AI offerings: Signals AI/“Xynthetica” AI-models-as-a-service launched Dec 2025, BioDesign). Software grew ~$36M in FY2025 and is the segment’s growth engine and margin/multiple story.

Customers: pharmaceutical and biotech R&D, academic and government research labs, and CROs. This segment is where Revvity is most cyclically exposed — to pharma/biotech capex, NIH/academic funding, and the biotech funding cycle.

Segment 2 — Diagnostics (~$1,425M FY2025, ~50% of revenue, +5% YoY). Three franchises:

• Reproductive Health / newborn screening (+$27M in FY2025) — DELFIA/DELFIA Xpress, GSP, Vanadis. Revvity is the global #1 in newborn and prenatal screening: instruments plus recurring assay kits for detecting genetic and metabolic disorders (Down syndrome, hypothyroidism, muscular dystrophy, metabolic conditions) mandated by public-health screening programs. This is the crown-jewel moat — high share, high switching costs, razor/razorblade consumables, and regulatory/reimbursement entrenchment.
• Immunodiagnostics (+$41M in FY2025) — the EUROIMMUN franchise (acquired 2017): autoimmune-disease and infectious-disease immunoassays with a very broad autoantibody test menu, plus IDS instruments. Note: management announced in May 2026 the divestiture of the China immunodiagnostics business (~6% of total revenue), which had been structurally pressured by China VBP/policy — leaving a higher-quality immunodiagnostics footprint concentrated in Europe/ROW.
• Applied Genomics — NGS library-prep and genomics workflow tools (NEXTFLEX, LabChip), reorganized into Life Sciences operationally in FY2025 but historically diagnostics-adjacent.

How it makes money / revenue quality. Revvity’s revenue is a mix of durable recurring streams (diagnostics assay kits, research reagents, software subscriptions, service) and cyclical hardware (instruments). Management characterizes roughly 80% of revenue as recurring — the reagents, consumables, assay kits, software subscriptions and service that generate repeat purchases off an installed base — with the remaining ~20% being lumpier instrument placements that seed future consumable pull-through. This recurring-heavy mix is the structural reason the business held up through the 2023–25 funding winter far better than a pure capital-equipment vendor would: when pharma and academic customers froze capital budgets, they largely kept buying consumables to run existing experiments and screens. Gross margin is ~55% (GAAP), with adjusted operating margins ~28%.

End markets and geography. By customer type, the business splits across (a) pharma/biotech R&D (the most cyclical, reagent- and instrument-heavy, ~the swing factor in Life Sciences), (b) academic and government research (grant-funded, NIH-sensitive), © clinical diagnostics labs and public-health screening programs (the most defensive, recurring, and reimbursement-driven — the Diagnostics anchor), and (d) CROs and applied/industrial. Geographically the business is genuinely global, with a meaningful European footprint (EUROIMMUN is German-headquartered and Europe-strong) and — historically — substantial China exposure that is now being deliberately reduced via the immunodiagnostics divestiture. The remaining China business skews toward Life Sciences, where management sees a better competitive position and cited accelerating reagent growth into 2026.

Verdict: A well-constructed, above-average-quality collection of franchises — genuinely excellent in newborn screening, solid in immunodiagnostics and reagents, and cyclically exposed in instruments/Life Sciences. It is a good business; the question the rest of this report presses is whether it is a good growth business at this price.

3. Industry Dynamics

Revvity straddles two structurally different industries, and conflating them is the single biggest analytical error one can make on this name. Roughly half of revenue (Life Sciences Solutions & Software) sits in the life-science tools & reagents industry; the other half (Diagnostics) sits in specialty in-vitro diagnostics — a more defensive, less pharma-cyclical profit pool.

Life-science tools & reagents — structurally good economics, but cyclically bruised, and RVTY occupies a subscale corner of it. The research antibodies & reagents market was ~$14–15B in 2024–25, growing ~7% CAGR toward ~$26B by 2033; flow-cytometry reagents specifically are ~$5.8B growing ~8% (MarketsandMarkets/SkyQuest, accessed 2026-07-18). The profit pool concentrates in recurring, high-margin single-use consumables — the razor/razorblade structure that gives Thermo, Danaher and Bio-Techne 40–70% reagent gross margins. But it is fragmented: the top 10 players hold only ~32% of revenue, and even #1 Thermo Fisher has just ~5% share. The instrument half (RVTY’s imaging — Opera Phenix, Operetta, Celigo — plus applied genomics) is the cyclical, lower-margin, capex-exposed slice that took the brunt of the 2023–25 destock.

The capital-cycle read (Marathon) is the one every peer report tells: a 2020–22 COVID/ZIRP demand-and-price bubble (PerkinElmer earned 63–65% gross and ~33% operating margins on COVID testing) followed by a synchronized 2023–25 “funding winter” across biopharma R&D budgets, academic/NIH grants and China. FY25 gross margin has reset to 54.8% and organic growth to low-single-digit. The cycle is bottoming but the recovery is shallow — RVTY’s 3–4% guide sits at the low end of the cohort’s aspirations (Thermo/Agilent ~5–7%, Danaher high-single-digit).

Specialty diagnostics — the better industry, and where RVTY’s real franchise lives. Newborn/reproductive screening is a ~$1.0B global market growing mid-to-high-single-digit, with an oligopolistic-to-monopolistic structure in the integrated dried-blood-spot platform; demand is non-discretionary and publicly funded (national screening mandates) — recession-resistant, but constrained by public-health budgets and, structurally, by declining developed-market birth rates (forward growth relies on menu expansion — more conditions screened per baby — plus emerging-market penetration, not birth volume). Autoimmune/infectious immunodiagnostics is a ~$6B market growing ~6% toward ~$11B by 2035; Roche leads (~20%), the field is competitive (Abbott, bioMérieux, Bio-Rad, Werfen, Thermo/Phadia, Siemens), but the autoantibody/indirect-immunofluorescence niche EUROIMMUN dominates is a defensible sub-pool, and EU IVDR / FDA re-registration raise barriers that favor entrenched incumbents.

Verdict: Diagnostics = structurally GOOD (defensive, regulation-entrenched, non-discretionary demand, oligopolistic in the crown-jewel newborn-screening pool). Life Sciences tools/reagents = good industry economics, but RVTY holds a subscale, fragmented, cyclically-exposed corner (a #4 antibody player plus cyclical imaging instruments). The blended business is more defensive than a pure-instrument name (Waters, Mettler) but grows slower and is more China/reimbursement-exposed. The China immunodiagnostics divestiture is itself a management admission that one slice of this industry — China IVD under volume-based procurement — is structurally impaired.

4. Competitive Position

The honest answer: the wide, financially-provable moat is in newborn/reproductive screening. Everything else ranges from moderate (EUROIMMUN autoimmune, BioLegend catalog, Signals software) to thin (imaging instruments, applied genomics). RVTY is a “one genuine crown jewel plus a portfolio of good-not-great franchises” story — not a uniformly wide-moat compounder like Danaher or Mettler.

Newborn screening (DELFIA / GSP / NeoBase / Specimen Gate) — Greenwald: economies of scale + customer captivity + regulatory entrenchment. WIDE. RVTY’s GSP analyzer plus DELFIA time-resolved-fluorescence chemistry screens well over 30% of all newborns worldwide across ~30+ countries. The mechanism is a razor/razorblade installed base: national/regional public-health labs install GSP/AutoDELFIA instruments, then buy proprietary CE-IVD/FDA-cleared consumable kits (NeoBase MS/MS, GSP neonatal panels, NeoLSD) for a decade-plus under multi-year national tenders. Switching requires re-validating assays, re-obtaining regulatory clearance, retraining staff and re-tendering — prohibitive for a public program where a missed diagnosis is a catastrophic liability. Pressure test: if this moat vanished, the Reproductive Health line’s recurring consumable revenue and the Diagnostics segment’s gross margin — RVTY’s highest-quality, stickiest stream — would deteriorate. This is precisely the revenue that holds through a downcycle. The “regulator” here is a government screening mandate, deeper than a pharmacopeia method-lock.

EUROIMMUN autoimmune immunodiagnostics — Greenwald: intangibles (menu breadth + proprietary EUROPattern IIFT) + installed-base captivity. MODERATE, narrower than the newborn moat. EUROIMMUN leads the autoantibody/indirect-immunofluorescence niche on the industry’s broadest autoimmune menu and its automated EUROPattern pattern-recognition platform, strongest in Europe. But it is a specialty leader, not the market leader (Roche leads the broader pool; Werfen and Thermo/Phadia are scaled competitors). Pressure test: eroding menu/IIFT differentiation hits immunodiagnostics growth and margin — and the China immunodiagnostics exit is live evidence that at the commoditized, VBP-exposed end the moat is already gone.

BioLegend research reagents — Greenwald: intangibles (citation/validation catalog). REAL BUT NARROW; a #4 challenger, not a leader. BioLegend holds the #4 overall global antibody-market share, focused on monoclonals and flow-cytometry reagents. The moat is catalog stickiness — once a specific clone/conjugate is written into a published, validated protocol, a researcher won’t re-validate a cheaper substitute. But BioLegend is a later-mover challenger against Thermo (Invitrogen/eBioscience, #1), BD Biosciences, Bio-Techne/R&D Systems, Merck/MilliporeSigma, Miltenyi and Abcam — and it competes partly on price/value, which a true wide-moat leader need not. This is the honest weak spot: the reagents/instruments half is differentiated but subscale versus the majors, and the agreed Merck KGaA acquisition of Bio-Techne (2026) creates a bigger, better-capitalized reagent rival.

Signals informatics/software (ChemDraw, Signals Notebook) — switching costs. SMALL BUT GENUINE. ChemDraw is near-ubiquitous in chemistry; ELN/data platforms carry real switching costs once embedded in R&D workflows — a modest, sticky, high-margin SaaS annuity, competing with Benchling and Dotmatics/Bruker. A nice-to-have, not a thesis-maker.

Financial signature of the moat. RVTY’s GAAP returns are uninterpretable for the same reason as Thermo/Danaher/Bio-Techne — a serial acquirer whose ~$9B intangible/goodwill base crushes GAAP metrics (FY25 GAAP op margin 12.5%, GAAP ROIC ~2.9%). On an adjusted basis operating margin is ~28% and adjusted ROIC is plausibly ~10–11% (cohort-consistent with Thermo’s ~11%). The genuine tell is the 54.8% consolidated gross margin holding through the downcycle — but note it has not held as tightly as Mettler (~59% flat) or Waters (~59% flat), which reflects a weaker aggregate moat than the best-in-cohort names.

Greenwald tests — market-share stability and the ROIC signature. Two diagnostics of a real moat: (1) stable market share over time, and (2) returns above the cost of capital that persist. On (1), newborn screening passes cleanly — Revvity (as PerkinElmer before it) has held its dominant global share for well over a decade, precisely because national screening contracts are sticky, multi-year and switching-cost-protected; share here does not oscillate the way it does in a genuinely competitive market. EUROIMMUN’s autoimmune-niche share has also been broadly stable, though the China exit is an admission of share loss at the commoditized end. BioLegend’s reagent share, by contrast, rose into the #4 slot — impressive, but rising challenger share in a fragmented market is a sign of a contest, not a settled moat. On (2), the test is more sobering: even normalizing out amortization, adjusted ROIC is only ~7–8% (see Financial Quality & Capital Allocation), which sits at the cost of capital — the return signature of a business with pockets of genuine moat (diagnostics) diluted by a large, expensively-acquired, only-averagely-advantaged reagents/instruments half. This is the quantitative reason to resist calling Revvity a “wide-moat compounder” in aggregate: the crown jewel is real, but it is not large enough relative to the whole to lift blended returns into clear moat territory.

Verdict: A genuinely wide moat in newborn/reproductive screening (dominant, regulation-entrenched, razor/razorblade — the crown jewel), wrapped in moderate franchises (EUROIMMUN, BioLegend #4 catalog, Signals) and one thin one (cyclical imaging instruments/applied genomics). A good business, not a great one — the diagnostics half carries the quality; the tools/reagents half is a subscale participant in a fragmented, cyclical market, and the ~7–8% blended adjusted ROIC confirms the moat does not (yet) dominate the economics.

5. Growth History and Forward Opportunities

History is distorted by two structural breaks: COVID and the New Mountain divestiture. Reported revenue fell from $3.83B (FY2021) to $2.86B (FY2025), but that decline is almost entirely (a) the roll-off of enormous COVID-diagnostics revenue that peaked in 2021, and (b) the 2023 sale of the ~$1.3B+ Analytical/Applied business. The “new Revvity” base has grown low-single-digit organically: FY2024 was roughly flat as pharma/biotech capex contracted and China weakened; FY2025 grew ~4% reported (~3% organic + ~1% FX); Q1 2026 delivered +3% total organic growth, described by management as the strongest reagent/instrument growth to pharma/biotech customers since 1H2023.

Segment growth FY2025: Life Sciences +2% (Software +$36M offsetting a slight Solutions decline of −$3M — i.e., the instruments/reagents core was roughly flat while software carried it); Diagnostics +5% (Immunodiagnostics +$41M, Reproductive Health +$27M). The pattern is telling: the durable, moaty diagnostics side is out-growing the more cyclical life-sciences side, and within Life Sciences, software (the highest-quality, highest-multiple sub-segment) is the growth. This composition matters for the multiple: a company whose growth is concentrated in software subscriptions and recurring diagnostics consumables should command a higher-quality-of-growth premium than one growing on instrument placements — the market is not yet paying for that mix.

The revenue bridge, plainly. The headline “revenue fell from $3.83B to $2.86B” is almost entirely non-organic: roughly $1B+ of COVID-diagnostics revenue evaporated between 2021 and 2023, and the New Mountain divestiture removed the legacy Analytical/Applied business. Strip both out and the continuing base has gone from roughly flat (FY24) to +3% organic (FY25) to +3–4% guided (FY26) — a low-but-positive, recovering trajectory. The important analytical move is to ignore the reported top-line decline entirely and focus on the ~$2.8B continuing base’s organic rate, which is the only number that speaks to the forward thesis.

Forward opportunities (the bull’s growth bridge):

1. Pharma/biotech recovery. Q1 2026 showed the first positive low-single-digit YoY growth from pharma/biotech reagent customers since early 2023; academic/government turned to mid-single-digit. If the biotech funding and pharma-capex cycle normalizes, the Life Sciences segment re-accelerates from ~flat toward mid-single-digits — the single biggest swing factor.
2. Software/AI (Signals). The fastest-growing, stickiest, highest-margin piece. New AI offerings (Xynthetica AI-models-as-a-service, BioDesign) extend the platform. Software growth mixes up both the growth rate and the multiple the market will pay.
3. Diagnostics menu expansion. Newborn-screening panel expansion (new disorders added to public programs), the EUROIMMUN autoimmune menu, and emerging-market reproductive-health penetration — durable, mid-single-digit-plus, recurring.
4. Portfolio focus. Exiting the structurally-broken China immunodiagnostics business (~6% of revenue, dilutive to growth and margin) mechanically raises the remaining company’s organic growth and margin — a “subtraction that improves the average.”

Forward guidance (FY2026, ex-China immunodiagnostics): organic growth 3–4%, adjusted operating margin ~28.4%, adjusted EPS $5.20–5.30.

Verdict: quality of growth is high; the rate of growth is the problem. What growth Revvity has is disproportionately the good kind — recurring diagnostics, software, reagents — not one-time instrument placements or acquired revenue. But the through-cycle organic rate (low-single-digit, ~3–4%) is structurally below the tools-and-diagnostics leaders, and the bull case rests on a cyclical pharma/biotech recovery that is visible but not yet proven. This is high-quality, low-velocity growth.

6. Financial Quality

The GAAP-vs-cash gap is the whole story. The single most important thing to understand about Revvity’s financials is that reported GAAP results are systematically depressed by non-cash acquisition accounting:

The ~$405M of D&A (of which acquired-intangible amortization is the dominant piece) and discrete items drive a ~$2.80/share wedge between GAAP and adjusted EPS. This is not earnings manipulation — amortization of acquired intangibles is a real, recurring, non-cash charge, and the adjusted numbers are the ones that reflect the cash the business actually throws off. But it does mean every headline GAAP multiple and return ratio on this stock is misleading, and it is why an own-history valuation screen flags a P/E in the 82nd percentile (rich) while the P/B sits in the 18th (cheap): the P/E is measuring the amortization shadow, not the earnings power.

Six-year financial arc (the COVID-and-divestiture distortion, quantified).

*FY2023 GAAP EPS inflated by the ~$514M discontinued-operations gain on the New Mountain sale. **FY2023 OCF depressed by working-capital/discontinued-ops timing. The table shows the two structural breaks clearly: the 2021 COVID-diagnostics revenue and margin peak (63–65% gross, ~33% operating), and the 2022–23 reset as COVID revenue rolled off and the legacy Analytical/Applied business was sold — leaving today’s ~$2.86B, 55%-gross-margin base. The gross-margin decline from 65% to 55% is real (COVID diagnostics were exceptionally high-margin, plus mix shift toward instruments/tariffs), and is a reminder that this is a good-not-elite gross-margin business versus Mettler/Waters at ~59% flat.

Margins and operating leverage. Gross margin ~54.8% (down ~104bps YoY on tariffs, FX and mix). Adjusted operating margin ~28% and guided to expand to ~28.4% in FY2026 — the margin trajectory is upward, aided by the China exit (accretive to margin) and cost discipline. Incremental margins are the watch item: a ~$2.9B-revenue business with 55% gross margins should drop a healthy share of incremental revenue to operating income if volume recovers.

Cash flow and conversion. FY2025 operating cash flow ~$583M; free cash flow ~$580–665M depending on definition (~20% FCF margin). Cash conversion of adjusted net income was ~87%, and management notes it would have been ~300bps higher excluding the China business being divested. This is genuine, high-quality free cash flow — the cash economics of a good tools/diagnostics business.

Balance sheet. Cash ~$920M; total debt ~$3.40B (short-term $589M + long-term $2.63B + leases $178M); net debt ~$2.3–2.5B; net debt/adjusted EBITDA ~2.8x. Critically, 100% of the debt is fixed-rate at a ~2.6% weighted-average coupon with ~6-year weighted maturity — a materially below-market cost of capital that is a hidden asset in a 4%+ rate environment. EBITDA/interest coverage ~8x. A ~$600M Eurobond due mid-July 2026 is slated to be repaid, taking gross leverage below 3× by year-end. The one balance-sheet caveat: tangible book value is negative (−$15/share) because $8.96B of goodwill and intangibles exceed equity — an artifact of the acquisitive history, not a solvency concern given the cash generation, but a reminder that the equity value is entirely a claim on intangible franchises and future cash flows.

Dilution, SBC and capital intensity. Stock-based compensation is modest for the sector at ~$23M in FY2025 (~0.8% of revenue) — a genuine positive versus software-heavy peers where SBC can be 5–10%+ of sales; Revvity’s “adjusted” earnings are not materially flattered by an SBC add-back, which lends them more credibility than the typical adjusted-EPS story. Net dilution has been negative — the aggressive buyback has shrunk the share count despite grants. Capital intensity is moderate: this is a reagents/instruments/software business, not a heavy-asset manufacturer; capex runs a low-single-digit percentage of sales, underpinning the ~87% FCF conversion. The one capital-structure caveat repeated for emphasis: the ~$8.96B goodwill-and-intangibles stack means book equity is entirely intangible and tangible book is negative — not a solvency issue given the cash flow and the cheap, laddered debt, but a reminder that the equity is a claim on franchise cash flows, not on hard assets.

Working capital. Cash-conversion cycle ~144 days (inventory-heavy, as a reagents/instruments business is); no red flags, stable YoY. Receivables and inventory scale with the business; the divestiture of the China immunodiagnostics unit is expected to modestly improve conversion (management cited ~+300bps to the already-solid ~87% adjusted-NI conversion excluding that business).

Verdict: do economics improve with scale? On an operating basis, yes — this is a high-gross-margin, high-FCF-conversion business with expanding adjusted margins and a cheap, well-laddered balance sheet. On a GAAP basis the economics look mediocre purely because of acquisition accounting. But the crucial distinction is between operating economics and return-on-capital: even normalizing out intangible amortization, adjusted ROIC is only ~7–8% — at or modestly below cost of capital, and the lowest of the large-cap tools trio (Danaher ~8% cash, Thermo ~11% adjusted). The underlying unit economics are good and improving; the returns on the ~$8.9B of goodwill/intangibles actually paid for the franchises are still only average-at-best. That gap — good operating margins, sub-par returns on deployed capital — is the legitimate bear-side counter to the “great business” framing, and the single most important reason the stock deserves some discount.

7. Capital Allocation

Revvity’s capital-allocation history is a story of three eras: (1) a serial-M&A build (EUROIMMUN 2017, BioLegend 2021, plus Oxford Immunotec, Nexcelom, Immunodiagnostic Systems, SIRION Biotech and others), (2) a reshape (the 2023 sale of the legacy Analytical/Applied/Enterprise-Services businesses to New Mountain Capital for ~$2.45B, funding the PerkinElmer→Revvity refocus), and (3) a return/prune era since 2023 dominated by aggressive buybacks and portfolio pruning rather than large deals.

M&A record — the defining, and most debatable, decisions.

The verdict on the build era is mixed and hinges on BioLegend: paying ~$5.25B (~13.8× sales) at the 2021 valuation peak was aggressive, and the resulting intangible amortization is precisely why GAAP returns look poor today. If BioLegend’s reagent revenue is compounding and holding margin, the deal is defensible; if it is a subscale #4 losing share to Thermo/Merck-Bio-Techne, the capital was over-paid. This is the single most important capital-allocation open question.

Shareholder returns. Since the 2023 refocus, management has pivoted decisively to buybacks: ~$821M repurchased in FY2025, ~$370M in FY2024, ~$86M in Q1 2026 — shrinking diluted share count from ~126M (2021) to ~112M (2025), roughly an ~11% reduction. The dividend is a token (~$0.28/share, ~0.3% yield, ~14% payout) — this is a growth/buyback company, not an income name. The buyback is largely FCF-funded (~$600M FCF), though FY2025’s $821M exceeded FCF, implying some balance-sheet funding (net debt was managed down only modestly). Buying back stock at ~21× forward earnings is accretive if organic growth re-accelerates and mediocre if it does not — the buyback is, in effect, a leveraged bet on the same growth-recovery thesis the equity embeds.

R&D and reinvestment. R&D is ~7.5% of sales (~$216M FY2025) — adequate for this mix (diagnostics/reagents need less R&D-intensity than a discovery-instrument pure-play), but not lavish; the growth engine is as much menu/software extension and M&A as organic invention.

Balance sheet as a capital-allocation asset. The debt is 100% fixed at a ~2.6% weighted-average coupon with ~6-year maturity — locked in at cycle-low rates, a genuine (and often overlooked) capital-allocation win that lowers the true cost of capital and makes the buyback math more favorable. The ~$600M Eurobond due mid-July 2026 is slated for repayment, taking gross leverage below 3× by year-end.

BioLegend’s economics deserve one more note in the company’s favor: ~40% of the ~$5.7B completed cost was paid in stock issued at $187.56 — roughly double today’s price. In hindsight management spent overvalued currency, materially softening the economic (if not the accounting) cost of the deal.

Incentive alignment (proxy, DEF 14A filed 2026-03-16). The design is above-average and demonstrably bites. Short-term (Global ICP) FY25 metrics: organic revenue growth 40% / adjusted EPS 40% / free-cash-flow conversion 20% — organic growth came in at 3.0% (80% of that component); overall ICP paid ~124% of target. Long-term (3-yr PRSUs): average organic growth, cumulative adjusted operating-margin expansion, cumulative cash-flow conversion, plus a relative-TSR modifier. The strongest pay-for-performance evidence: the 2023 LTIP paid 0% — three-year non-COVID organic growth of 2% (vs an 8% minimum), operating-margin expansion of −130bps (vs +100bps minimum), and relative TSR at the 28th percentile all missed, and the entire PRSU tranche vested at zero. CEO Singh total comp ~$13.8M FY25 (up ~16% YoY), pay ratio 239:1. Two caveats: (1) heavy reliance on adjusted EPS, which adds back the very acquisition amortization the M&A created (the classic serial-acquirer incentive tilt); and (2) ROIC is absent from the metric set — a gap versus Danaher, and notable for a company whose returns-on-capital are the crux of the bear case. Governance yellow flags: a 25-year-tenured non-executive Chair, and a 2026 shareholder Proposal (No. 5) demanding executives retain a meaningful share of equity pay (board recommends against) — a sign of outside-holder concern about management’s thin skin in the game.

Insider activity (27 Form 4s, Feb–Jun 2026). Zero code-P open-market purchases. Every transaction is routine — annual grants (code A), tax-withholding on vest (code F), and 10b5-1 option-exercise-and-sell (code M/S). Aggregate officer/director ownership is <1% of shares outstanding (CEO ~0.4%); top holders are index funds. This is a neutral-to-mildly-negative signal: the selling is programmatic, not a conviction dump, but in a stock down ~45% from its highs the complete absence of a single discretionary open-market purchase by any insider is a missing bullish tell.

Verdict: rehabilitated, not vindicated. The post-2023 record — disciplined divestitures, cheap fixed-rate financing, FCF-funded buybacks, a plan that paid 0% when performance missed — is competent, shareholder-friendly stewardship. But the M&A legacy is an overhang the returns-on-capital have not yet outrun: reported ROIC has collapsed from ~12% (2020) to ~2.5–2.9% (2023–25), and even normalizing out intangible amortization, adjusted ROIC is only ~7–8% — at or modestly below an ~8–9% WACC, and below both Danaher (~8% cash) and Thermo (~11% adjusted). BioLegend at a peak-cycle price is the proximate cause: a great franchise bought without the scale or operating system to grow into it fast enough. Management is not destroying capital today — the buyback/prune/de-lever program is the right response to a low-return reinvestment environment — but value creation from here depends entirely on organic re-acceleration lifting returns above cost of capital. Combined with <1% insider ownership and the Proposal-5 revolt, the honest label is competent-stewardship-of-an-over-paid-portfolio.

8. Changes and Headwinds — Last Two Years

Strategic changes.

• China immunodiagnostics divestiture (2026) — the most consequential recent move: exiting a ~6%-of-revenue business structurally impaired by China’s volume-based-procurement and local-competition dynamics. Announced via LOI (~$200M) in April 2026 and confirmed on the May 2026 call; accretive to the remaining company’s growth and margin, and a clear signal that management will prune rather than defend structurally-broken positions.
• FY2025 re-segmentation — reorganized into Life Sciences Solutions & Software and Diagnostics (Immunodiagnostics + Reproductive Health), folding Applied Genomics operationally into Life Sciences.
• Software/AI push — Signals platform extended with Signals AI, Xynthetica (AI-models-as-a-service, Dec 2025) and BioDesign (cloud-native biologics design, 2026) — the growth/margin/multiple story.

Cyclical/environmental developments.

• Pharma/biotech + academic recovery (nascent). Q1 2026 delivered the first positive YoY pharma/biotech reagent growth since 1H2023 and mid-single-digit academic growth — the clearest evidence yet that the 2023–25 funding winter is thawing. Not yet proven durable.
• Tariffs and FX — cut FY2025 gross margin ~104bps; an ongoing cost headwind, partly offset by pricing and mix.

Sector M&A read-across. The agreed Merck KGaA acquisition of Bio-Techne (2026) cuts both ways: it plants a larger, better-capitalized reagent competitor next to BioLegend, and it re-focused investor attention on cheap, high-quality tools/diagnostics assets — with the market briefly bidding RVTY in sympathy as a possible consolidation candidate.

Leadership. CEO Prahlad R. Singh and CFO Max Krakowiak remain in place; no destabilizing management turnover.

Verdict: on balance, the changes strengthen the thesis. The China exit removes the single biggest structural overhang, the software push improves the growth/margin mix, and the pharma/biotech recovery — if durable — is the swing factor. The offsetting negatives (a bigger reagent competitor, tariff/FX drag) are real but second-order. The net direction of the last two years is toward a cleaner, more focused, higher-quality — if still slow-growing — company.

9. Risk Analysis

Catastrophic-loss risk is low. This is a cash-generative, investment-grade-style balance sheet with durable diagnostics franchises; the realistic downside is multiple compression and a stalled thesis, not impairment of the enterprise. The tail risk is a prolonged tools-and-diagnostics downturn compounding a China/geopolitical shock.

10. Valuation Discussion (Embedded Expectations)

Where it trades. At ~$110: market cap ~$12.3B, enterprise value ~$14.6B. On the meaningful (cash) metrics: ~21× forward adjusted EPS ($5.25 midpoint), ~16× adjusted EBITDA, ~5.3× EV/sales, ~5% FCF yield. On GAAP: ~50× trailing EPS and ~17.5× GAAP EBITDA — figures that should be discarded for the reasons set out under Financial Quality.

Relative to peers, Revvity trades at a clear discount to the life-sciences-tools quality leaders. The comp set (peer metrics per recent public filings; RVTY at ~$110):

TECH multiples reflect the agreed Merck KGaA takeout, not standalone. Read: RVTY is the cheapest name in the cohort on forward P/E (~21× vs 19–28×) at a mid-pack adjusted operating margin (~28%, above Thermo/Agilent, below Mettler/Bio-Techne). The discount is rational, not a free lunch: it prices (1) the lowest organic growth in the group (3–4%), (2) the China immunodiagnostics overhang, (3) messy GAAP optics from EUROIMMUN/BioLegend amortization, and (4) a less-pristine “compounder” narrative than DHR/MTD. Whether that is value or a value trap turns on the growth-re-acceleration question — but the quality case rests almost entirely on the diagnostics half.

Own-history valuation percentiles (ignore the P/E percentile — GAAP-distorted): P/S in the ~65th percentile of its own multi-year range and P/B in the ~18th percentile — i.e., not expensive versus its own history, and cheap on book. Composite ~55th percentile.

Embedded-expectations read. At ~21× forward earnings with ~3–4% organic growth and a ~5% FCF yield, the market is underwriting Revvity as a low-growth, high-cash-conversion compounder — essentially pricing in continuation of low-single-digit organic growth with steady margin expansion and buyback-driven EPS growth (mid-to-high-single-digit EPS CAGR). What the price is not underwriting is a sustained re-acceleration of organic growth to mid-single-digits: if the pharma/biotech and academic recovery visible in Q1 2026 proves durable and organic growth settles at 4–5%+, both the earnings and the multiple could re-rate toward the peer group (a ~$130+ zone at ~25× the same EPS). Conversely, if organic growth stalls back toward 1–2%, the “quality compounder” thesis breaks and the multiple compresses toward the high-teens (a ~$90 zone at ~17–18×).

Reverse-DCF / cash-yield cross-check. With ~$600M of free cash flow on a ~$12.3B equity value, the stock offers a ~5% FCF yield. For that to translate into a ~9–10% equity return, FCF must compound at ~4–5% — which requires low-single-digit organic revenue growth plus continued buyback accretion plus modest margin expansion, all of which are in management’s guide. In other words, at ~$110 the market is paying for the base case to simply be delivered, with little embedded credit for re-acceleration and little penalty priced for a relapse. That symmetry is why the risk/reward reads as “fair,” not “cheap”: the ~5% starting yield plus mid-single-digit FCF growth is a reasonable but unexceptional ~9–10% expected return, before any multiple change. The optionality is the multiple: a re-rate from ~21× toward the ~25× quality-group median on evidence of durable 4–5% organic growth is the bull’s incremental ~20% — and the mirror risk is a de-rate to the high-teens if growth stalls. Note also the ~7–8% adjusted ROIC (see Financial Quality & Capital Allocation): a business earning ~cost-of-capital returns on its deployed base should trade at a discount to peers earning double-digit spreads — the valuation gap is not purely a growth artifact, it partly reflects genuine capital-efficiency.

Scenario framing (illustrative, forward adjusted EPS ~$5.25):

• Bear (~17× / stalled growth): ~$90 — organic growth relapses toward 1–2%, tools cycle stays soft, discount widens, buyback looks like a growth-substitute.
• Base (~21× / 3–4% organic): ~$110 — roughly today; the market’s current view — low-single-digit organic + margin creep + buyback = mid-to-high-single-digit EPS growth.
• Bull (~25× / durable mid-single-digit re-acceleration + software mix-up): ~$130+ — re-rate toward the quality-leader group as the pharma/biotech recovery proves durable and adjusted margins push past 29–30%.

An upside asymmetry worth naming: strategic/consolidation optionality. At ~21× earnings with a wide-moat diagnostics crown jewel and a cheap fixed-rate balance sheet, Revvity is a plausible consolidation participant — the agreed Merck KGaA/Bio-Techne combination (2026) is the live precedent the market read across. A ~$12B enterprise is a large bite, but not implausible for the mega-cap tools players; this is a real (if unquantifiable) tail-right skew to the setup.

No price target; no recommendation. The above are embedded-expectations scenarios, not calls.

11. Variant Perception

Consensus view. Sell-side is roughly balanced-to-constructive: recent targets cluster ~$115 (Bernstein, Market Perform) to ~$125 (Evercore, Outperform), i.e., modest upside from ~$110. Consensus treats Revvity as a decent-quality, low-growth tools/diagnostics name that is cheap versus peers for a reason (slower growth), with the China exit and pharma recovery as incremental positives.

Strongest bull case. The market is anchoring on GAAP optics and a trough in the cycle. On cash economics this is a ~28%-margin, ~$600M-FCF, buyback-shrinking, moaty-diagnostics business with a cheap fixed-rate balance sheet, trading at ~21× earnings and ~5% FCF yield — a discount that closes as (a) pharma/biotech recovers and organic growth re-accelerates to mid-single-digits, (b) the China divestiture and software mix lift the growth/margin average, and © the amortization headwind rolls off over time, converging GAAP toward cash. Optionality: sector consolidation — Revvity’s cheap multiple and high-quality assets make it a plausible acquisition/consolidation participant (note Bio-Techne’s June 2026 agreed takeover by a German strategic, which the market read across to RVTY).

Strongest bear case. The discount is earned and stable. Half the business is a cyclical, less-differentiated reagents/instruments operation whose organic growth is structurally ~low-single-digit; the marquee BioLegend deal loaded ~$5B+ of goodwill/intangibles that still depress real returns on deployed capital; buying back stock at ~21× earnings is a mediocre use of FCF if growth doesn’t inflect; and the “adjusted” earnings capitalize on excluding a very real, recurring amortization charge. In this view Revvity is a ~mid-single-digit-EPS-grower that deserves its ~20× multiple and offers little edge.

Where I think consensus may be slightly offsides. The balanced sell-side view treats Revvity as “cheap for a reason — slow growth.” That is directionally right but may under-weight three things: (1) the structural cleanup — the market has not fully credited that the remaining company post-China is a higher-growth, higher-margin, higher-cash-conversion entity than the reported blended figures suggest; (2) the fixed-rate balance sheet as a genuine per-share value driver in a higher-rate world (2.6% coupon, 6-year maturity — a hidden asset most models ignore); and (3) the buyback compounding — shrinking the share count ~2–3%/year off a ~5% FCF yield adds materially to per-share value even at flat organic growth. Against that, consensus may be too generous on the buyback’s accretion if it is partly debt-funded, and too quick to treat “adjusted EPS” as clean when it capitalizes real recurring amortization. On net, the risk/reward looks genuinely two-sided — which is exactly why the analytical body of this report takes no position.

The 3–5 assumptions that matter most:

1. Does organic growth re-accelerate to ≥4–5% and hold? (Bull-critical; the whole re-rate depends on it.)
2. Is the pharma/biotech + academic recovery in Q1’26 durable or a head-fake?
3. Are BioLegend/EUROIMMUN generating adequate cash returns on the capital paid? (Capital-allocation verdict.)
4. Does the China exit + software mix structurally lift growth and margin, or just shrink the company?
5. Will management keep funding buybacks from FCF (accretive) rather than re-levering (value-neutral)?

Falsification: the bull case is falsified if two-plus quarters show organic growth relapsing toward 1–2% with instruments still declining; the bear case is falsified if organic growth prints 4%+ for several quarters with instrument demand inflecting and adjusted margins pushing past 29–30%.

Factor-positioning read (where the tape supports the variant view). In factor space RVTY is an abandoned/derated life-sciences-tools name in the early innings of a recovery — not a crowded momentum trade. The style loadings are the antithesis of a chased winner: strongly negative Momentum (−0.30 to −0.61 across models), elevated realized vol (negative LowVol), Value near zero, modestly positive Quality, and a dominant sector/thematic loading (a custom “life-sciences powerhouse” basket +0.95, health-care sector +0.58) — i.e., it trades as a sector bet, not a style bet. The risk-adjusted record is a textbook derated name bottoming: 5-yr annualized −6.0% (Sharpe −0.23), 3-yr −2.3%, lifetime max drawdown −63%, but 1-yr +18% and the latest quarter de-annualizing to ~+25% raw. This supports the bull’s “consensus is anchored on GAAP optics and a cyclical trough” claim — the negative long-run alpha and Momentum loading show the market has not crowded into this name. The regime caveat matters, though: the loadings co-move with the entire tools group (Agilent, Danaher, Thermo, Waters, Bio-Techne, Mettler are all >0.95 factor-similar), so the “recovery” is largely a bet on the group’s regime turning, and the multi-year negative track record is the prior any bull must overcome. It is a sector-thematic, higher-vol, quality-ish name repricing off capitulation lows — not a factor-pure value signal.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the cash ROIC on BioLegend specifically (revenue/margin today vs the ~$5.25B paid)? The single most important capital-allocation question.
2. How much of the FY2026 margin expansion is China-exit mix vs genuine operating leverage?
3. What is the sustainable organic growth of the remaining company post-China, by segment?
4. Is the $821M FY2025 buyback fully FCF-funded, or partly debt/balance-sheet-funded (share count fell but net debt was managed down only modestly)?
5. How competitive is Signals/AI software versus Benchling, Dotmatics (Bruker) and Schrödinger — is the software growth durable?
6. Newborn-screening: how much menu-expansion / birth-rate headwind is embedded in the diagnostics growth rate?

14. What Must Be True

Bull case — what must be true: Organic growth re-accelerates from ~3% toward mid-single-digits and holds as pharma/biotech and academic funding normalize; software (Signals/AI) compounds double-digit and mixes up the growth/margin profile; adjusted margins push past ~29–30%; the China exit and portfolio focus structurally lift the average; and buybacks continue to shrink the share count from FCF. In that world Revvity re-rates toward the quality-tools group.

Falsification test: two consecutive quarters of organic growth relapsing to ≤2% with instrument revenue still declining, and/or adjusted margins flat-to-down — the re-acceleration thesis is dead.

Bear case — what must be true: The tools cycle stays soft or double-dips; organic growth is structurally stuck at ~1–3% regardless of macro; BioLegend/EUROIMMUN returns remain mediocre on cash-ROIC; and the ~21× multiple compresses toward the high-teens as the market concludes it is paying up for a low-growth roll-up.

Falsification test: organic growth prints 4%+ for three-plus quarters with instrument demand inflecting and adjusted margins expanding past 29% — the “structurally-stuck, deserves-a-discount” thesis is dead.

APPENDIX A — Standard Diligence Questionnaire

Company: Revvity, Inc. (NYSE: RVTY) · Report date: 2026-07-18 Labels: [F] Fact · [I] Interpretation · [A] Assumption.

General

What thoughtful questions have other investors asked? The recurring investor debates: (1) Is Revvity structurally a low-single-digit organic grower, or is the current ~3% a cyclical trough that recovers to mid-single-digits? (2) What is the cash return on the ~$5.25B BioLegend deal? (3) How much of the GAAP-to-adjusted EPS gap is “real” recurring amortization the market should capitalize? (4) Is the aggressive buyback the best use of FCF versus M&A or debt paydown? (5) Post-China-divestiture, what is the true growth/margin profile of the remaining company?

Cyclicality & Earnings Nature

• Cyclical high or low? [I] Near a cyclical low — FY2024 was roughly flat as pharma/biotech capex contracted; Q1’26 showed the first pharma/biotech reagent growth since 1H2023. Earnings are off the COVID-inflated 2021 peak and recovering, not extended.
• External environment vs internal action? [I] Both — the depressed level reflects the external tools/biotech-funding cycle; the improving margin/EPS reflects internal cost discipline, portfolio pruning (China exit) and buybacks.
• Revenue stability? [I] Above-average — roughly half is recurring diagnostics/reagents/software; instruments (~cyclical) are the swing factor.
• Market size / outlook? [F/I] Global life-sciences-tools (~$70B+) and specialty diagnostics markets; low-to-mid-single-digit structural growth, faster in software/AI and diagnostics menu expansion. (See Industry Dynamics.)

Business Quality & Competitive Moat

• Industry more or less competitive? (See Industry/Competitive sections.) Newborn screening: concentrated, entrenched. Reagents/instruments: competitive vs Thermo/Danaher/Agilent.
• How profitable (ROIC/ROE)? [F] GAAP ROE ~4%, ROIC ~3% — depressed by acquisition amortization. [I] Adjusted ROE ~8%; adjusted ROIC only ~7–8% (ex-amortization, at/below WACC — lowest of the large-cap tools trio). Adjusted operating margin ~28%.
• Industry profitability / barriers? [I] Diagnostics side has real regulatory/switching-cost barriers (newborn-screening programs, IVDR); reagents have catalog/scale barriers; instruments are more contestable.
• Easily understood? [I] Yes — a two-segment tools/diagnostics business, though the acquisition accounting obscures the economics.
• Undermined by low-cost foreign labor? [I] Low risk — IP/regulatory/quality-gated products, not labor-arbitrage goods.
• Do brands matter? [I] Yes in diagnostics (EUROIMMUN, DELFIA) and reagents (BioLegend) — installed-base and menu reputation drive stickiness.
• Switching costs? [I] High in diagnostics (validated assays, regulatory approval, LIS integration) and software; moderate in reagents; lower in standalone instruments.

Financial Condition & Balance Sheet

• Assets not on the balance sheet? [I] The value of the newborn-screening installed base and EUROIMMUN/BioLegend franchises exceeds book; conversely, goodwill/intangibles ($8.96B) overstate the balance sheet vs tangible value (tangible book is negative).
• Off-balance-sheet liabilities? [F] Operating leases capitalized; no unusual off-B/S exposure identified.
• Accounting conservatism? [I] Standard for the sector; the key adjustment (add-back of acquired-intangible amortization) is legitimate but capitalizes a real recurring charge — treat adjusted EPS with that caveat.
• CapEx intensity? [F/I] Moderate — this is a reagents/instruments/software business, not heavy-asset; FCF conversion ~87% of adjusted NI.

Capital Allocation & Management

(See Capital Allocation section for the full record.)

• FCF generation & use? [F] ~$600M FCF/yr; used predominantly for buybacks ($821M FY25) and debt management; small dividend.
• Recent acquisitions? [F] Pivoted away from large M&A toward buybacks post-2023; recent activity is divestitures (New Mountain 2023 ~$2.45B; China immunodx 2026 ~$200M LOI). Prior build: EUROIMMUN 2017 (~$1.3B), BioLegend 2021 (~$5.25B announced/~$5.7B completed, ~13.8× sales, ~41% stock issued at $187.56).
• Buying back shares? [F] Yes, aggressively — share count 126M→112M since 2021 (~11%). FY23 $389M, FY24 $370M, FY25 $821M.
• Issuing shares to insiders? [F] SBC modest (~$23M FY25); not dilutive at scale.
• Comp / management motivation? [F] ICP metrics: organic growth 40% / adj EPS 40% / FCF conversion 20%. LTIP: organic growth + margin expansion + cash conversion + relative-TSR modifier. 2023 LTIP paid 0% (genuine 3-yr miss) — strong pay-for-performance evidence. [I] ROIC absent from metrics (a gap); heavy adj-EPS reliance adds back the acquisition amortization. CEO comp $13.8M FY25 (+16% YoY), ratio 239:1. [F] Aggregate insider ownership <1%, zero open-market buys; shareholder Proposal 5 (equity retention) — board against. [I] Returns-on-capital are the crux: reported ROIC ~2.5–2.9%, adjusted ROIC only ~7–8% (at/below WACC), lowest of the large-cap tools trio.

Valuation & Market Data

• ADR / MLP / K-1? [F] No — U.S. C-corp common stock, standard 1099.
• Dividend policy? [F] Token dividend (~$0.28/sh, ~0.3% yield, ~14% payout) — a growth/buyback company, not an income name.
• Net income vs CFO divergence? [F] CFO ($583M) far exceeds GAAP net income ($241M) — because of the large non-cash amortization; this supports the quality of cash earnings rather than flagging a concern.

Risks & Downside

• What would cause the stock to decline? [I] A stalled organic-growth recovery (relapse to 1–2%), a prolonged tools/biotech downturn, a China/tariff shock, or evidence the BioLegend capital was poorly deployed → multiple compression toward the high-teens.
• Catastrophic-loss risk? [I] Low — cash-generative, investment-grade-style balance sheet, durable diagnostics franchises.
• Total-loss risk? [I] Negligible — no going-concern/solvency issue; leverage moderate and cheaply financed.

Recent News & Events

• [F] China immunodiagnostics divestiture announced May 2026 (LOI ~$200M, ~6% of revenue) — de-risks the biggest structural overhang.
• [F] Q1 2026 beat (May 5): +3% organic, 23.6% adj op margin, $1.06 adj EPS; pharma/biotech turned positive.
• [F] Signals AI / Xynthetica / BioDesign software launches (Dec 2025–Jun 2026).
• [F] Sector M&A read-across: Bio-Techne agreed takeover (Jun 2026) refocused attention on cheap, high-quality tools assets including RVTY.
• [F] FY2025 re-segmentation into Life Sciences Solutions & Software + Diagnostics.

APPENDIX B — Source Appendix

Company: Revvity, Inc. (NYSE: RVTY) · Report date: 2026-07-18

All non-obvious facts in this report trace to the sources below. Primary sources (SEC filings, company disclosure) are prioritized; third-party aggregated data (ROIC.ai and a public factor model) is used for computed ratios and positioning, reconciled to filings.

Primary — SEC filings & company disclosure

Company / corporate history

Third-party aggregated data (computed ratios / positioning; reconciled to filings)

Third-party / media

Peer comparisons drawn from the public filings of Agilent (A), Danaher (DHR), Thermo Fisher (TMO), Mettler-Toledo (MTD), Waters (WAT) and Bio-Techne (TECH).